Trulicity 1,5 mg 0,5 ml pen injectors 4 pcs

Trulicity 1,5 mg 0,5 ml pen injectors 4 pcs

Composition:

Dulaglutide 1,5 mg.

Inactive ingredients:

Sodium citrate dihydrate, anhydrous citric acid, mannitol, polysorbate 80 (vegetable), water for injection.

Properties:

Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. The hypoglycemic effect of dulaglutide is due to several mechanisms of action of GLP-1. At elevated glucose concentrations, dulaglutide increases the content of intracellular cyclic adenosine monophosphate (cAMP) in pancreatic β-cells, which leads to an increase in insulin secretion. Dulaglutide suppresses excess secretion of glucagon in patients with type 2 diabetes mellitus, which leads to a decrease in hepatic glucose release. In addition, dulaglutide slows down the rate of gastric emptying.

In patients with type 2 diabetes mellitus, starting from the first dose, dulaglutide improves glycemic control due to a sustained reduction in fasting, preprandial and postprandial blood glucose concentrations, which is maintained for a week until the next dose.

Indications:

Trulicity is indicated in adults with type 2 diabetes to improve glycemic control:

- as monotherapy in case diet and exercise do not provide the necessary glycemic control in patients who are not shown the use of metformin due to intolerance or contraindications;

- as part of combination therapy in combination with other hypoglycemic drugs, including insulin, if these drugs, together with diet and exercise, do not provide the necessary glycemic control.

Directions for use:

• Trulicity should be injected subcutaneously into the abdomen, thigh or upper arm.

The injection sites should be rotated every week. You can use the same site, but be sure to choose different points for injection.

• The drug must not be administered intravenously or intramuscularly.

• The drug can be administered at any time of the day, regardless of the intake of food.

Monotherapy:

The recommended dose is 0.75 mg once a week.

Combination Therapy:

The recommended dose is 1.5 mg once a week.

• In patients aged 75 years and older, the recommended initial dose of the drug is 0.75 mg 1 time per week.

• The drug is not recommended for use in children and adolescents under 18 years of age.

Trulicity is administered once a week. The patient should make a note on the calendar so as not to forget the next dose.

• When the patient presses the green injection button, the pen will automatically insert the needle into the skin, inject the drug, and remove the needle after the injection is completed.•Before you start using the syringe pen, you must.

- Get the drug out of the refrigerator.

Check the label to make sure the correct product is taken and that it has not expired.

- Inspect the pen (do not use it if the pen is damaged or the drug is cloudy, discolored or contains particles).

Wash the hands.

Instructions for Use:

1. Remove the cap and make sure the pen is locked.

Remove the gray cap covering the base.

Do not put the cap back on as this may damage the needle. Do not touch the needle.

2. Firmly press the transparent base to the skin surface at the injection site.

Unlock by turning the locking ring.

3. Press and hold the green injection button until you hear a loud click.

You must continue to firmly press the transparent base against the skin until a second click is heard. This will happen when the needle starts to retract, after about 5-10 seconds.

4. The injection is completed when the gray part of the mechanism becomes visible.

Side effects:

• From the side of metabolism and nutrition: 

Often: Hypoglycemia

• From the gastrointestinal tract:

Often: Nausea, diarrhea, vomiting1, abdominal pain, decreased appetite, dyspepsia, constipation, flatulence, bloating, gastroesophageal reflux disease, belching

• Common:

Weakness

• Laboratory and instrumental data:

Often:

Sinus tachycardia, atrioventricular (AV) block I degree.

Contraindications:

- hypersensitivity to the active or any of the excipients that make up the drug;

- type 1 diabetes mellitus;

- diabetic ketoacidosis;

- severe renal dysfunction;

- chronic heart failure;

- pregnancy;

- period of breastfeeding;

- severe diseases of the gastrointestinal tract, incl. severe paresis of the stomach;

- acute pancreatitis;

-children and adolescents up to 18 years of age.

Warnings and precautions:

• Dulaglutide should be used with caution in patients taking oral medications that require rapid absorption from the gastrointestinal tract. A delay in the rate of gastric emptying may slightly increase the exposure of sustained-release preparations by increasing the time of release of the drug.

• There are glass parts in the syringe pen. Handle the device with care. If the patient drops it on a hard surface, the pen should not be used. It is necessary to use a new syringe pen for injection.

• The pen must be disposed of in a sharps container or as recommended by your healthcare professional.

• If the patient has visual impairment, he should not use the Trulicity® single-dose pen without the assistance of a person specially trained in its use.

Storage:

The syringe pen should be stored in the original carton to protect from light, out of the reach of children.

The pen should be stored in the refrigerator.

If after purchase at the pharmacy storage in the refrigerator is not possible, you should store the syringe pen at a temperature not exceeding 30 ° C for no more than 14 days.

Do not freeze the pen. If the pen has been frozen, do not use it.

Package:

The cardboard box contains a plastic container with 4 pre - filled syringe pens and paper instructions.